Frontiers in Immunology Submission Guide (2026)

The submission portal requires ORCID registration for all authors before you can start. Don't begin formatting your manuscript until every co-author has an ORCID ID. The system won't let you proceed without them.

• Required documents:
• Cover letter (specific template requirements)
• Manuscript file (LaTeX or Word)
• Figure files (minimum 300 DPI, maximum 10MB each)
• Data availability statement
• Competing interests declaration
• Ethics statements (IRB approval numbers, patient consent documentation)

• Formatting specifics:

Word limit varies by article type. Original Research allows 12,000 words including references. Reviews can go up to 15,000 words. Methods articles are capped at 8,000 words. The portal counts words automatically and will block submission if you exceed limits.

Figures can be embedded in the manuscript file during initial submission. If accepted, you'll need to provide high-resolution separate files. The journal accepts color figures without additional fees, unlike many traditional publishers.

The cover letter template is specific. You need: research question, methodology summary, key findings, clinical relevance statement, and suggested reviewers. Use these cover letter examples as templates, but customize for Frontiers' collaborative review philosophy.

• Submission checklist:
• All authors have ORCID IDs
• Specialty section selected
• Word count within limits
• Ethics approvals documented
• Data sharing plan included
• Competing interests declared
• Three suggested reviewers provided

The portal saves your progress automatically. You can submit in multiple sessions. But once you hit "submit," you can't modify anything. Triple-check your specialty section choice before final submission.

Average time to first decision is 80 days, but this varies by specialty section and manuscript complexity. Systematic reviews take longer than original research. Clinical trials with patient data get expedited review.

• Timeline breakdown:
• Editorial screening: 7-14 days
• Reviewer recruitment: 14-21 days
• Peer review period: 30-45 days
• Editorial decision: 7-10 days

The collaborative review model encourages reviewers to see each other's comments and build consensus. You'll get more constructive feedback than adversarial criticism. Reviewers know their comments are shared, which tends to make reviews more professional and helpful.

• During review:

You can track progress through the submission portal. Status changes from "Under Review" to "Required Reviews Completed" to "Editor Decision Started." Don't contact the editorial office unless the process exceeds 90 days.

If reviewers request major revisions, you get 60 days to respond. Minor revisions have a 30-day deadline. The system sends automatic reminders as deadlines approach.

• Revision strategy:

Address every reviewer comment specifically. The collaborative model means reviewers will see your response and judge whether you've addressed their concerns adequately. Don't dismiss any feedback, even if you disagree.

The biggest mistake is assuming Frontiers has lower standards because the journal publishes at scale. The broader scope changes throughput, but editors still filter hard for translational relevance, section fit, and methodological credibility.

• Top rejection triggers:

1. Poor clinical context - Describing molecular mechanisms without connecting to disease or therapy
2. Weak systematic review methodology - Missing PROSPERO registration, inadequate search strategies, no quality assessment
3. Wrong specialty section - Submitting autoimmunity research to Clinical Immunology section

Authors often submit basic immunology papers because they think Frontiers will accept anything. The journal wants translational relevance, not just novel biology. If your T-cell study doesn't connect to autoimmune disease, cancer, or vaccines, try a basic immunology journal instead.

Systematic reviews fail when methodology is sloppy. Register your protocol with PROSPERO before starting. Use multiple databases for literature searches. Include quality assessment tools like Newcastle-Ottawa or Cochrane risk-of-bias. The journal publishes many systematic reviews, but only rigorous ones.

• Original Research (60% of publications): Clinical studies, translational research, biomarker validation. Basic mechanistic studies need strong clinical relevance. Sample sizes matter less than study design quality.

• Reviews (25% of publications): Systematic reviews and meta-analyses perform better than narrative reviews. PRISMA compliance is mandatory. Expert opinion pieces rarely get accepted unless from recognized thought leaders.

• Clinical Trial (10% of publications): Phase I-III trials, real-world effectiveness studies, post-market surveillance data. Requires trial registration and follows CONSORT guidelines.

• Methods (5% of publications): New techniques, protocols, or analytical approaches. Must demonstrate advantage over existing methods with validation data.

Success varies by article type and section. Systematic reviews often perform better when methodology is strong, while original research and clinical trial papers face more direct scrutiny on section fit, ethical handling, and translational value.

Position your work appropriately. Don't submit a narrative review when you could do a systematic review. Don't call a case series "original research" when it belongs in Clinical Trial category.

Compare options based on your career stage and research type. Consider these factors when choosing journals alongside Frontiers' specific strengths and limitations.

• Choose Nature Immunology if: Your basic research has broad immunological significance, you have strong mechanistic data, and you can wait 6+ months for review.

• Choose Immunity if: You're reporting paradigm-shifting findings, have comprehensive experimental validation, and prioritize prestige over publication speed.

• Choose Journal of Immunology if: Your work is solid basic immunology without clinical connection, you prefer traditional peer review, and you want faster publication than Nature journals.

• Choose Clinical Immunology if: Your research focuses specifically on clinical applications, you have patient data, and you want a specialized audience over broad readership.

Frontiers works best for translational research that connects basic findings to clinical relevance. If your paper sits between basic and clinical research, Frontiers offers a good middle ground with reasonable review times and constructive feedback.

The collaborative review model suits early-career researchers who benefit from detailed, educational feedback. Senior researchers who prefer traditional anonymous review might find other journals more comfortable.

Before you upload, run your manuscript through a Frontiers in Immunology submission readiness check to catch the issues editors filter for on first read.

In our pre-submission review work with manuscripts targeting Frontiers in Immunology, five patterns generate the most consistent desk rejections worth knowing before submission.

According to Frontiers in Immunology submission guidelines, each pattern below represents a documented desk-rejection trigger; per SciRev data and Clarivate JCR 2024 benchmarks, addressing these before submission meaningfully reduces early-rejection risk.

• Basic immunology paper without a clinical or translational anchor (roughly 35%). The Frontiers in Immunology author guidelines position the journal as publishing immunology research with translational or clinical relevance, and the collaborative review process is designed to evaluate manuscripts where the disease or therapeutic connection is visible from submission. In our experience, roughly 35% of desk rejections involve manuscripts that describe novel molecular pathways or immune cell biology without connecting the findings to disease, therapy, or patient outcomes. Editors specifically screen for manuscripts where the clinical or translational consequence is present in the framing, not implied from the mechanism alone.

• Systematic review submitted without PROSPERO registration (roughly 25%). In our experience, we find that roughly 25% of systematic review and meta-analysis submissions arrive without a registered protocol in PROSPERO or an equivalent prospective registration, or with search strategies and quality assessment tools missing from the supplementary materials. In practice, editors consistently reject systematic reviews where the methodology documentation is incomplete at submission, because the journal's standards for evidence synthesis treat pre-registration and transparent search reporting as submission requirements rather than revision-stage corrections.

• Specialty section choice misaligned with the immunology paper (roughly 20%). In our experience, roughly 20% of submissions are routed to a specialty section whose editorial standards and reviewer pool do not match the manuscript's study design, patient population, or research question. Editors explicitly consider whether the specialty section fits the manuscript before accepting for review, because section-level selectivity at Frontiers is materially different from overall journal-level selectivity.

• Clinical study too small for the target specialty section's bar (roughly 15%). In our experience, roughly 15% of submissions to competitive sections such as Clinical Immunology arrive with patient cohort sizes that fall well below the sample sizes that section editors and reviewers expect for the clinical claims being made. In our analysis of submission difficulties at Frontiers in Immunology, this pattern is most common in submissions where the section was chosen for topic fit without checking the typical study scale in that section's recent publications.

• Cover letter explains the science but not the clinical consequence (roughly 10%). In our experience, roughly 10% of submissions arrive with cover letters that describe the immunological mechanisms studied without stating what the findings mean for patient care, drug development, or clinical decision-making. Editors explicitly consider whether the cover letter makes the translational case before routing the paper for collaborative review.

SciRev author-reported review times and Clarivate JCR 2024 bibliometric data provide additional benchmarks when planning your submission timeline.

Before submitting to Frontiers in Immunology, a Frontiers in Immunology submission readiness check identifies whether your translational framing, systematic methodology, and section choice meet the editorial bar before you commit to the submission.

• Is Frontiers in Immunology a Good Journal? An Honest Assessment for 2026 - Use a fuller journal-evaluation page before deciding whether the fit is right
• Is Frontiers in Immunology a Good Journal? An Honest Assessment for 2026 - Reputation analysis and career considerations
• Journal Cover Letter Template: 5 Filled-In Examples for Any Journal - Cover letter templates and examples

Getting your manuscript ready for submission? Manusights provides detailed pre-submission reviews to catch formatting issues, scope mismatches, and editorial red flags before you submit.